ATE254461T1 - Behandlung von augenschmerzen - Google Patents

Behandlung von augenschmerzen

Info

Publication number
ATE254461T1
ATE254461T1 AT01910734T AT01910734T ATE254461T1 AT E254461 T1 ATE254461 T1 AT E254461T1 AT 01910734 T AT01910734 T AT 01910734T AT 01910734 T AT01910734 T AT 01910734T AT E254461 T1 ATE254461 T1 AT E254461T1
Authority
AT
Austria
Prior art keywords
treatment
eye pain
pain
eye
brimonidine
Prior art date
Application number
AT01910734T
Other languages
English (en)
Inventor
Daniel W Gil
Michael E Stern
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE254461T1 publication Critical patent/ATE254461T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01910734T 2000-02-15 2001-02-15 Behandlung von augenschmerzen ATE254461T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18260900P 2000-02-15 2000-02-15
PCT/US2001/004851 WO2001060347A2 (en) 2000-02-15 2001-02-15 Method for treating ocular pain

Publications (1)

Publication Number Publication Date
ATE254461T1 true ATE254461T1 (de) 2003-12-15

Family

ID=22669224

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910734T ATE254461T1 (de) 2000-02-15 2001-02-15 Behandlung von augenschmerzen

Country Status (8)

Country Link
US (1) US6294553B1 (de)
EP (1) EP1265601B1 (de)
JP (1) JP4970685B2 (de)
AT (1) ATE254461T1 (de)
AU (2) AU3831301A (de)
CA (1) CA2400377C (de)
DE (1) DE60101265T2 (de)
WO (1) WO2001060347A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
EP2131651B1 (de) * 2007-03-12 2013-05-22 Sarentis Therapeutics, Inc. Topische hornhautschmerzmittel mit neurotensin-rezeptoragonisten
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009039356A1 (en) * 2007-09-20 2009-03-26 Allergan, Inc. Treatment methods with brimonidine
JP5580210B2 (ja) * 2007-12-21 2014-08-27 ガルデマ ラボラトリーズ インコーポレイテッド 手術前治療
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
US20180369240A1 (en) * 2008-08-01 2018-12-27 Eye Therapies Llc Preferential Vasoconstriction Compositions and Methods of Use
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) * 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2329849B1 (de) 2009-11-18 2015-04-29 Galderma Research & Development Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
MX2012010823A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
JP2013524275A (ja) 2010-04-03 2013-06-17 ドシ，プラフル 薬剤を含む医療機器、その製造方法とその使用方法
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
EP2798077A2 (de) 2011-12-31 2014-11-05 Allergan, Inc. Hochempfindlicher zellbasierter test für den nachweis der anwesenheit von aktivem botulinum-neurotoxin-serotyp-a
US10004734B2 (en) * 2016-01-26 2018-06-26 Warren Scherer Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
WO2024015959A1 (en) 2022-07-15 2024-01-18 Praful Doshi Methods of making and using contact lenses including medicaments and stabilizers of labile components such as drugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129890T1 (de) * 1990-09-07 1995-11-15 Univ Alicante Komposition für die behandlung von augenschmerzen.
WO1995010280A1 (en) * 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
AU715350B2 (en) * 1995-05-12 2000-01-20 Allergan, Inc. Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
CZ183799A3 (cs) * 1996-11-25 1999-09-15 The Procter & Gamble Company Sloučenina, farmaceutický prostředek a způsob prevence nebo léčby
JP4783502B2 (ja) * 1997-12-04 2011-09-28 アラーガン、インコーポレイテッド α２Ｂまたは２Ｂ／２Ｃアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体
ES2239466T3 (es) * 1998-10-20 2005-09-16 Omeros Corporation Solucion de irrigacion y metodo de inhibicion del dolor y de la inflamacion.
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions

Also Published As

Publication number Publication date
DE60101265D1 (de) 2003-12-24
CA2400377A1 (en) 2001-08-23
EP1265601B1 (de) 2003-11-19
JP2003522785A (ja) 2003-07-29
CA2400377C (en) 2007-11-27
AU2001238313C1 (en) 2004-11-04
JP4970685B2 (ja) 2012-07-11
US6294553B1 (en) 2001-09-25
AU2001238313B2 (en) 2004-05-27
WO2001060347A2 (en) 2001-08-23
US20010031754A1 (en) 2001-10-18
EP1265601A2 (de) 2002-12-18
AU3831301A (en) 2001-08-27
WO2001060347A3 (en) 2002-02-28
HK1051499A1 (en) 2003-08-08
DE60101265T2 (de) 2004-08-26

Similar Documents

Publication Publication Date Title
DE60101265D1 (de) Behandlung von augenschmerzen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE383852T1 (de) Kupferchelatbildner zur behandlung von augenentzündungen
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE60103685D1 (de) Behandlung von Poriomania
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
ATE422944T1 (de) Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DE60138371D1 (de) PROSTAGLANDINE zur Behandlung von Lichtstrahlung erzeugten Augenerkrankungen wie Photoretinitis
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
LU91009B1 (de) Behandlung von Verbrennungen
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60108241D1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
DE60302495D1 (de) Landwirtschaftliche Maschine zur Behandlung von Erntegut

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties